###begin article-title 0
Inhibition of HIF2alpha Is Sufficient to Suppress pVHL-Defective Tumor Growth
###end article-title 0
###begin article-title 1
Inhibition of HIF2alpha Protein Suppresses pVHL-Driven Tumor Growth
###end article-title 1
###begin p 2
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 213 216 213 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene (VHL) is linked to the development of hereditary (VHL-associated) and sporadic clear-cell renal carcinomas as well as other abnormalities. The VHL gene product, pVHL, is part of an E3 ubiquitin ligase complex that targets the alpha subunits of the heterodimeric transcription factor HIF (hypoxia-inducible factor) for degradation in the presence of oxygen. Here we report that a HIF2alpha variant lacking both of its two prolyl hydroxylation/pVHL-binding sites prevents tumor inhibition by pVHL in a DNA-binding dependent manner. Conversely, downregulation of HIF2alpha with short hairpin RNAs is sufficient to suppress tumor formation by pVHL-defective renal carcinoma cells. These results establish that tumor suppression by pVHL is linked to regulation of HIF target genes.
###end p 2
###begin p 3
Specific downregulation of the transcription factor HIF2alpha is sufficient to suppress tumor formation by cells lacking the functional tumor suppressor (pVHL), demonstrating that tumor suppression by pVHL is linked to regulation of HIF target genes
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 148 159 148 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>
###xml 525 528 525 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 570 573 570 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 718 736 718 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Zhuang1">Zhuang et al. 1995</xref>
###xml 738 758 738 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Lubensky1">Lubensky et al. 1996</xref>
###xml 760 781 760 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Mandriota1">Mandriota et al. 2002</xref>
###xml 833 836 833 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 1058 1080 1058 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>
###xml 1082 1100 1082 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Gnarra2">Gnarra et al. 1996</xref>
###xml 1102 1124 1102 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Schoenfeld1">Schoenfeld et al. 1998</xref>
###xml 166 174 <span type="species:ncbi:405018">cardinal</span>
von Hippel-Lindau (VHL) disease is caused by heterozygous germline inactivation of the VHL tumor suppressor gene, which resides on chromosome 3p25 (Kaelin 2002). The cardinal feature of this hereditary cancer syndrome is the development of multiple vascular tumors, called hemangioblastomas, in the central nervous system and retina, as well as an increased risk of clear-cell carcinoma of the kidney and pheochromocytoma. Tumor development in VHL disease is linked to somatic inactivation or loss of the remaining wild-type VHL allele, leading to loss of the wild-type VHL gene product, pVHL. In the kidney, this event occurs very early, as it has been documented in epithelial cells lining premalignant renal cysts (Zhuang et al. 1995; Lubensky et al. 1996; Mandriota et al. 2002). Consistent with Knudson's two-hit model, somatic VHL mutations are also common in sporadic clear-cell renal carcinomas and hemangioblastomas. Conversely, restoration of pVHL function is sufficient to suppress tumor formation by pVHL-defective renal carcinoma cells in vivo (Iliopoulos et al. 1995; Gnarra et al. 1996; Schoenfeld et al. 1998).
###end p 5
###begin p 6
###xml 154 165 154 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>
###xml 369 369 361 361 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"/>
###xml 593 604 573 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>
###xml 1377 1399 1341 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos2">Iliopoulos et al. 1996</xref>
###xml 1401 1423 1365 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Knebelmann1">Knebelmann et al. 1998</xref>
###xml 1425 1444 1389 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>
###xml 1446 1468 1410 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-de1">de Paulsen et al. 2001</xref>
###xml 355 360 <span type="species:ncbi:9606">human</span>
pVHL is the substrate recognition module of an E3 ubiquitin ligase complex that contains elongin B, elongin C, Cul2, and Rbx1 (also called ROC1 or Hrt1) (Kaelin 2002). This complex targets the alpha subunits of the heterodimeric transcription factor HIF (hypoxia-inducible factor) for polyubiquitination and hence proteasomal degradation. There are three human HIFalphaproteins (HIF1alpha, HIF2alpha, and HIF3alpha). Enzymatic hydroxylation of conserved prolyl residues within these proteins by members of the egg-laying-defective nine (EGLN) family is required for their recognition by pVHL (Kaelin 2002). This posttranslational modification is inherently oxygen-dependent. Accordingly, HIFalpha subunits are normally unstable in the presence of oxygen, but are stabilized under low-oxygen (hypoxic) conditions. In contrast, cells lacking wild-type pVHL fail to degrade HIFalpha subunits in the presence of oxygen, and thus hypoxia-inducible gene products are constitutively overproduced. Among these proteins are vascular endothelial growth factor (VEGF) and platelet-derived growth factor B, implicated in angiogenesis; phosphoglycerate kinase and glucose transporter 1 (GLUT1), involved in glucose uptake and metabolism; and transforming growth factor alpha (TGFalpha), which can establish a mitogenic autocrine loop with the epidermal growth factor (EGF) receptor (EGFR) (Iliopoulos et al. 1996; Knebelmann et al. 1998; Maxwell et al. 1999; de Paulsen et al. 2001).
###end p 6
###begin p 7
###xml 576 596 576 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Clifford1">Clifford et al. 2001</xref>
###xml 598 617 598 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Hoffman1">Hoffman et al. 2001</xref>
###xml 706 709 706 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 863 878 863 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Ang1">Ang et al. 2002</xref>
###xml 996 1015 996 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Vincent1">Vincent et al. 2000</xref>
###xml 1017 1034 1017 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Elson1">Elson et al. 2001</xref>
###xml 1036 1053 1036 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Rebar1">Rebar et al. 2002</xref>
###xml 1189 1209 1189 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Clifford1">Clifford et al. 2001</xref>
###xml 1211 1230 1211 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Hoffman1">Hoffman et al. 2001</xref>
Tumor-derived pVHL mutants are typically defective with respect to HIF polyubiquitination in vivo, and the HIF target genes cited above are implicated in tumorigenesis. Thus, correlative data and biological plausibility support a role for HIF in pVHL-defective tumor formation. Nonetheless, emerging genotype-phenotype correlations in VHL disease suggest that pVHL has multiple functions. For example, pVHL mutants associated with a low risk (type 2A VHL disease) and high risk (type 2B disease) of renal cell carcinoma are similarly defective with respect to HIF regulation (Clifford et al. 2001; Hoffman et al. 2001). Interestingly, individuals with Chuvash polycythemia are homozygous for a hypomorphic VHL allele that is quantitatively defective with respect to HIF regulation, which leads to overproduction of erythropoietin in vivo but not tumor formation (Ang et al. 2002). Moreover, forced activation of HIF target genes has not led to tumor formation in the animal models tested so far (Vincent et al. 2000; Elson et al. 2001; Rebar et al. 2002). Conversely, some pVHL mutants that retain the ability to regulate HIF are linked to familial pheochromocytoma (type 2C VHL disease) (Clifford et al. 2001; Hoffman et al. 2001). Collectively, these findings suggest that tumor formation following pVHL inactivation reflects the loss of multiple pVHL functions in a context-dependent manner.
###end p 7
###begin p 8
###xml 187 204 183 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
###xml 320 323 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
In this report we provide data that strengthen our earlier conclusion that inhibition of HIF2alpha is necessary for pVHL-dependent suppression of renal carcinoma tumor formation in vivo (Kondo et al. 2002). Moreover, we provide evidence that inhibition of HIF2alpha is likewise sufficient to suppress tumor formation by VHL(-/-) renal carcinoma cells in vivo. Collectively, these results indicate that HIF2alpha is a critical downstream target of pVHL with respect to suppression of renal carcinogenesis.
###end p 8
###begin title 9
Results and Discussion
###end title 9
###begin title 10
Inhibition of HIF2alpha Target Genes Is Necessary for Tumor Suppression by pVHL
###end title 10
###begin p 11
###xml 85 101 77 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Ivan1">Ivan et al. 2001</xref>
###xml 103 123 95 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Jaakkola1">Jaakkola et al. 2001</xref>
###xml 125 139 117 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Yu1">Yu et al. 2001</xref>
###xml 330 347 314 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
###xml 552 569 532 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
###xml 743 761 711 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Masson1">Masson et al. 2001</xref>
###xml 850 867 814 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
###xml 1687 1704 1631 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
Hydroxylation of HIF1alpha Pro564 or HIF2alpha Pro531 generates a pVHL-binding site (Ivan et al. 2001; Jaakkola et al. 2001; Yu et al. 2001). We previously showed that a HIF2alpha variant in which Pro531 was replaced by alanine (HIF2alpha P531A) escaped recognition by pVHL and induced the expression of HIF target genes in vivo (Kondo et al. 2002). Moreover, HIF2alpha P531A abrogated pVHL-dependent tumor suppression in vivo, implying that HIF is functionally downstream of pVHL and that inhibition of HIF is necessary for tumor suppression by pVHL (Kondo et al. 2002). Shortly thereafter, it was shown that hydroxylation of HIF1alpha Pro404 (corresponding to HIF2alpha Pro405) creates a second potential pVHL-binding site within HIF1alpha (Masson et al. 2001). Although we could not detect a physical interaction between pVHL and HIF2alpha P531A (Kondo et al. 2002), the identification of a second potential pVHL-binding site left open the possibility that the biological effects of HIF2alpha P531A were due, at least partly, to perturbation of pVHL function as a result of direct binding. If true, this would undermine the conclusions described above. Moreover, we had not established whether the biological effects of HIF2alpha P531A required that it bind to DNA, as would be expected if its oncogenic effects were due to transcriptional activation of specific hypoxia-inducible promoters. To this end, we repeated our earlier experiments using retroviral vectors encoding HIF2alpha P405A;P531A or HIF2alpha P405A;P531A;bHLH*. The latter contains a five amino acid substitution within the HIF2alpha basic helix-loop-helix (bHLH) domain that leads to loss of DNA-binding capability (Kondo et al. 2002).
###end p 11
###begin p 12
###xml 75 97 71 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>
###xml 99 118 95 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>
###xml 165 184 157 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>
###xml 485 507 473 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>
###xml 509 513 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos2">1996</xref>
###xml 515 533 503 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Gnarra2">Gnarra et al. 1996</xref>
###xml 535 557 523 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Schoenfeld1">Schoenfeld et al. 1998</xref>
###xml 559 578 547 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>
###xml 580 602 568 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Davidowitz1">Davidowitz et al. 2001</xref>
###xml 674 696 662 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>
###xml 997 1005 973 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g001">Figure 1</xref>
###xml 1288 1310 1252 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>
786-O renal carcinoma cells lack wild-type pVHL and overproduce HIF2alpha (Iliopoulos et al. 1995; Maxwell et al. 1999). HIF1alpha is not detectable in these cells (Maxwell et al. 1999). Reintroduction of wild-type pVHL into 786-O cells by stable transfection does not affect cell growth in vitro under standard serum-rich growth conditions, but leads to downregulation of HIF2alpha protein levels, suppression of hypoxia-inducible gene expression, and impaired tumorigenesis in vivo (Iliopoulos et al. 1995, 1996; Gnarra et al. 1996; Schoenfeld et al. 1998; Maxwell et al. 1999; Davidowitz et al. 2001). A 786-O subclone stably transfected to produce wild-type pVHL (WT8) (Iliopoulos et al. 1995) was infected with a retrovirus encoding HIF2alpha P405A;P531A or HIF2alpha P405A;P531A;bHLH* and grown under hypoxic (1% oxygen) or normoxic (21% oxygen) conditions. As expected, HIF2alpha was only detectable under hypoxic conditions in WT8 cells and in WT8 cells infected with an empty retrovirus (Figure 1A). In contrast, HIF2alpha was readily detectable under both hypoxic and normoxic conditions in WT8 cells infected to produce either of the two HIF2alpha P405A;P531A variants. Indeed, the levels of HIF2alpha present in these cells approximated those seen in a 786-O subclone (PRC3) (Iliopoulos et al. 1995) that, unlike WT8 cells, was stably transfected with an empty expression plasmid and hence still lacks wild-type pVHL.
###end p 12
###begin p 13
###xml 151 159 143 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g001">Figure 1</xref>
###xml 238 255 226 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
###xml 346 350 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 375 383 359 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g001">Figure 1</xref>
###xml 351 356 <span type="species:ncbi:10090">mouse</span>
Neither HIF2alpha P405A;P531A nor HIF2alpha P405A;P531A;bHLH* affected the proliferation of WT8 cells in vitro under standard cell culture conditions (Figure 1B). In contrast, but in keeping with our earlier results with HIF2alpha P531A (Kondo et al. 2002), HIF2alpha P405A;P531A restored the ability of WT8 cells to form large tumors in vivo in nude mouse xenograft assays (Figure 1C). HIF2alpha P405A;P531A;bHLH* did not promote tumor formation by WT8 cells, implying that tumor promotion by HIF2alpha P405A;P531A is linked to its ability to act as a sequence-specific DNA-binding transcriptional regulator. These results, together with our earlier findings, indicate that inhibition of HIF2alpha is necessary for tumor suppression by pVHL.
###end p 13
###begin title 14
Loss of HIF2alpha Is Sufficient to Suppress pVHL-Defective Tumor Growth In Vivo
###end title 14
###begin p 15
###xml 128 131 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 799 807 771 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g002">Figure 2</xref>
###xml 927 935 895 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g002">Figure 2</xref>
###xml 937 938 905 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g002">2</xref>
###xml 1340 1348 1304 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g003">Figure 3</xref>
To ask whether inhibition of HIF2alpha is likewise sufficient for tumor suppression by pVHL, we set out to inhibit HIF2alpha in VHL(-/-) renal carcinoma cells using short hairpin RNAs (shRNA). We tested five HIF2alpha shRNAs based on 19mer sequences that are unique to HIF2alpha according to GenBank. Two such shRNAs (#2 and #3) decreased HIF2alpha protein levels, as determined by anti-HIF2alpha immunoblot analysis and by diminished activity of a cotransfected HRE-luciferase reporter plasmid, when transiently introduced into 786-O cells (data not shown). Infection of 786-O cells with retroviruses encoding shRNA #2 or #3, but not the parental retrovirus, led to decreased steady-state levels of HIF2alpha protein as well as decreased levels of GLUT1, which is encoded by a HIF-responsive gene (Figure 2A). Downregulation of HIF2alpha did not affect cell growth in vitro, but was sufficient to impair tumor growth in vivo (Figure 2B-2D). The former observation is consistent with the finding that pVHL does not inhibit cell proliferation under standard cell culture conditions and argues against the idea that the latter was due to nonspecific toxicity. Moreover, these in vivo effects could be prevented by coadministration of a retrovirus encoding an HIF2alpha mRNA with silent third-base mutations within the shRNA recognition site (Figure 3) and were not observed with retroviruses encoding a scrambled HIF2alpha shRNA or luciferase shRNA (data not shown). Thus, tumor suppression by the HIF2alpha shRNA was unlikely to reflect a spurious interaction with an unintended target.
###end p 15
###begin p 16
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 132 135 132 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 262 282 262 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Lonergan1">Lonergan et al. 1998</xref>
###xml 494 502 490 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g004">Figure 4</xref>
###xml 597 616 585 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Maxwell2">Maxwell et al. 1999</xref>
###xml 920 941 892 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Mandriota1">Mandriota et al. 2002</xref>
###xml 1172 1193 1136 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Carmeliet1">Carmeliet et al. 1998</xref>
###xml 198 207 <span type="species:ncbi:10090">nude mice</span>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
To ask whether these findings could be extended to other VHL(-/-) renal carcinoma cell lines, we repeated these experiments in A498 VHL(-/-) renal carcinoma cells. Tumor formation by these cells in nude mice is diminished following restoration of pVHL function (Lonergan et al. 1998). In keeping with the results obtained with 786-O cells, downmodulation of HIF2alpha levels with shRNA did not affect A498 cell growth in vitro (data not shown), but dramatically inhibited tumor growth in vivo (Figure 4A). It is noteworthy that both 786-O cells and A498 cells produce HIF2alpha and not HIF1alpha (Maxwell et al. 1999). It will be important in the future to ask whether disruption of HIF2alpha is sufficient to suppress tumor formation by pVHL-defective cells that produce both HIFalpha paralogs. In this regard, studies of renal precursor lesions in VHL patients suggest that HIF2alpha is more oncogenic than HIF1alpha (Mandriota et al. 2002). It is tempting to speculate that loss of HIF1alpha expression in some pVHL-defective renal carcinoma cells confers a selective advantage in vivo, perhaps related to the ability of HIF1alpha to induce apoptosis in some settings (Carmeliet et al. 1998).
###end p 16
###begin p 17
###xml 137 140 137 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 200 218 200 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Gnarra1">Gnarra et al. 1994</xref>
###xml 220 241 220 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Takahashi2">Takahashi et al. 2002</xref>
###xml 651 659 647 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio.0000083-g004">Figure 4</xref>
###xml 803 806 795 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Several histological renal carcinoma variants have been recognized, including clear-cell carcinoma and papillary (chromophil) carcinoma. VHL mutations are common in the former, but not in the latter (Gnarra et al. 1994; Takahashi et al. 2002). Interestingly, the small A498 tumors that did form in the presence of HIF2alpha shRNA consisted of malignant cells forming tubulopapillary structures, corresponding to papillary (chromophil) renal carcinoma histology, whereas the empty vector tumors consisted primarily of sheets of clear cells, as would be seen in typical clear-cell renal carcinoma, with interspersed areas displaying papillary features (Figure 4B). This suggests that dysregulation of HIF2alpha is causally linked to the clear-cell pattern and is consistent with the tight linkage between VHL mutations and this renal carcinoma subtype.
###end p 17
###begin p 18
###xml 187 206 183 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Maxwell1">Maxwell et al. 1997</xref>
###xml 208 229 204 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Carmeliet1">Carmeliet et al. 1998</xref>
###xml 231 247 227 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Ryan1">Ryan et al. 1998</xref>
###xml 249 253 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Ryan2">2000</xref>
###xml 255 272 251 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Hopfl1">Hopfl et al. 2002</xref>
###xml 355 366 351 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>
###xml 496 513 492 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Haase1">Haase et al. 2001</xref>
###xml 515 531 511 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Mack1">Mack et al. 2003</xref>
###xml 340 345 <span type="species:ncbi:9606">human</span>
###xml 376 381 <span type="species:ncbi:10090">mouse</span>
###xml 772 777 <span type="species:ncbi:9606">human</span>
Most of the work performed so far with respect to the oncogenic effects of HIF has focused exclusively on HIF1alpha, where both prooncogenic and antioncogenic effects have been reported (Maxwell et al. 1997; Carmeliet et al. 1998; Ryan et al. 1998, 2000; Hopfl et al. 2002). Likewise, loss of pVHL is prooncogenic in a restricted subset of human tissues (Kaelin 2002). In the mouse, loss of pVHL promotes hemangioma development in the liver, but inhibits tumor formation by embryonic stem cells (Haase et al. 2001; Mack et al. 2003). These observations conform to the emerging paradigm that the same mutation can be either prooncogenic or antioncogenic, depending on the molecular and cellular context. Therefore, one must be cautious in extrapolating our findings beyond human clear-cell renal carcinomas.
###end p 18
###begin p 19
###xml 72 90 72 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Zhuang1">Zhuang et al. 1995</xref>
###xml 92 112 92 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Lubensky1">Lubensky et al. 1996</xref>
###xml 114 135 114 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Mandriota1">Mandriota et al. 2002</xref>
###xml 186 189 186 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 513 531 509 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Lowden1">Lowden et al. 1994</xref>
###xml 533 557 529 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Chailler1">Chailler and Briere 1998</xref>
###xml 559 575 555 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Ramp2">Ramp et al. 2000</xref>
###xml 577 599 573 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-de1">de Paulsen et al. 2001</xref>
###xml 1017 1028 1009 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>
###xml 1176 1187 1168 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kaelin1">Kaelin 2002</xref>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 506 511 <span type="species:ncbi:10090">mouse</span>
###xml 724 730 <span type="species:ncbi:9606">humans</span>
Loss of pVHL in the human kidney gives rise to premaligant renal cysts (Zhuang et al. 1995; Lubensky et al. 1996; Mandriota et al. 2002). It is presumed that additional mutations at non-VHL loci are required for conversion to frank renal cell carcinomas. It will therefore be of interest to determine whether dysregulation of HIF is sufficient to produce renal cysts. In this regard, TGFalpha, which is encoded by a HIF target gene, is a potent renal mitogen and is sufficient to induce renal cysts in the mouse (Lowden et al. 1994; Chailler and Briere 1998; Ramp et al. 2000; de Paulsen et al. 2001). On the other hand, our data do not exclude the possibility that the development of renal pathology following pVHL loss in humans reflects a complex interplay between dysregulated HIF2alpha and loss of a second pVHL function. pVHL has been implicated in control of cell-cycle, differentiation, and extracellular matrix formation, although the extent to which these activities are due to control of HIF is not known (Kaelin 2002). A number of non-HIF pVHL-binding partners have, however, been reported, including atypical protein kinase C members, VDU1, SP1, and fibronectin (Kaelin 2002).
###end p 19
###begin title 20
Therapeutic Implications
###end title 20
###begin p 21
###xml 576 593 564 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Mydlo1">Mydlo et al. 1989</xref>
###xml 595 612 583 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Lager1">Lager et al. 1994</xref>
###xml 614 636 602 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Knebelmann1">Knebelmann et al. 1998</xref>
###xml 638 660 626 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-de1">de Paulsen et al. 2001</xref>
###xml 714 732 702 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Fabbro1">Fabbro et al. 2002</xref>
###xml 864 881 852 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Walke1">Walke et al. 1991</xref>
###xml 883 900 871 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Brown1">Brown et al. 1993</xref>
###xml 902 923 890 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Takahashi1">Takahashi et al. 1994</xref>
###xml 925 942 913 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Nicol1">Nicol et al. 1997</xref>
###xml 944 960 932 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Ramp1">Ramp et al. 1997</xref>
###xml 1041 1059 1029 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Fabbro1">Fabbro et al. 2002</xref>
###xml 1189 1205 1177 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Yang1">Yang et al. 2003</xref>
###xml 1033 1039 <span type="species:ncbi:9606">humans</span>
Our findings strengthen the notion that inhibition of HIF2alpha might be therapeutically useful in pVHL-defective clear-cell renal carcinoma. On the other hand, sequence-specific DNA-binding transcription factors have not proven to be attractive drug targets to date. For this reason, it will be important to determine which HIF2alpha target genes are necessary for its oncogenic activity. Among the known HIF targets, the abovementioned TGFalpha and its cognate receptor, EGFR, are frequently overproduced in renal carcinoma and are suspected to establish an autocrine loop (Mydlo et al. 1989; Lager et al. 1994; Knebelmann et al. 1998; de Paulsen et al. 2001). A number of EGFR are presently in clinical trials (Fabbro et al. 2002). Likewise, overproduction of VEGF is common in renal cell carcinoma and likely contributes to tumor angiogenesis in this setting (Walke et al. 1991; Brown et al. 1993; Takahashi et al. 1994; Nicol et al. 1997; Ramp et al. 1997). Drugs directed against VEGF or its receptors are also being tested in humans (Fabbro et al. 2002). In a recent Phase II study, a neutralizing VEGF antibody was shown to delay disease progression in metastatic renal carcinoma (Yang et al. 2003) and offers hope that rational combinations of small molecules directed against HIF targets will alter the natural history of this disease.
###end p 21
###begin title 22
Materials and Methods
###end title 22
###begin title 23

###end title 23
###begin title 24
Plasmids
###end title 24
###begin p 25
###xml 100 117 92 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
###xml 614 631 602 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
pBABE-puro-HA-HIF2alpha P405A;P531A was generated by two-step PCR. The pcDNA3.0-HA-HIF2alpha P531A (Kondo et al. 2002) insert was first amplified with primer A (5'-GCGCGGATCCGCCACCATGACA-3') and primer B (5'-TCCTGGGGTAGCAGCCAGCTG-3') or primer C (5'-CAGCTGGCTGCTACCCCAGGA-3') and primer D (5'-GCGCCAATTGTCAGGTGGCCTGGTC-3'). Aliquots of these two PCRs were then mixed and amplified with primers A and D. The resulting PCR product was digested with BamHI and MunI and ligated into pBABE-puro-HA vector cut with BamHI and EcoRI. In parallel, similar reactions were carried out with pcDNA3.0-HA-HIF2alpha P531A/bHLH* (Kondo et al. 2002) as the PCR template to make pBABE-puro HA-HIF2alpha P405A;P531A;bHLH* (conversion of amino acids residues 24-29, RCRRSK to ACAASA).
###end p 25
###begin p 26
###xml 996 1019 976 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Brummelkamp1">Brummelkamp et al. 2002</xref>
Short interfering RNAs (siRNAs) corresponding to two unique HIF2alpha 19mer sequences (#2, 5'-GACAAGGTCTGCAAAGGGT-3' and #3, 5'-GGAGACGGAGGTGTTCTAT-3') downregulated HIF2alpha protein levels and HIF-dependent transcriptional activity. Synthetic oligonucleotides spanning the #2 siRNA sequence (5'-GATCCCCGACAAGGTCTGCAAAGGGTTTCAAGAGAACCCTTTGCAGACCTTGTCTTTTTGGAAA-3' and 5'-AGCTTTTCCAAAAAGACAAGGTCTGCAAAGGGTTCTCTTGAAACCCTTTGCAGACCTTGTCGGG-3') or the #3 sequence (5'-GATCCCCGGAGACGGAGGTGTTCTATTTCAAGAGAATAGAACACCTCCGTCTCCTTTTTGGAAA and 5'-AGCTTTTCCAAAAAGGAGACGGAGGTGTTCTATTCTCTTGAAATAGAACACCTCCGTCTCCGGG-3') were annealed by incubation in 30 mM HEPES-KOH (pH 7.4), 100 mM potassium acetate, 30 mM HEPES-KOH, 2 mM Mg-acetate for 4 min at 95degreesC followed by 10 min at 70degreesC. The resulting duplex oligonucleotides were phosphorylated with T4 polynucleotide kinase (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's protocol and ligated into pRETRO-SUPER vector (Brummelkamp et al. 2002) cut with BglII and HindIII.
###end p 26
###begin p 27
###xml 82 83 78 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 85 86 81 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 88 89 84 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
The pBABE-hygro-HA-HIF2alpha siRNA recognition site mutant for #3 siRNA (5'-GGAGACCGAAGTCTTCTAT-3') (called HIF2alpha MT) was generated by two-step PCR. The pcDNA3.0-HA-HIF2alpha insert was first amplified was first amplified with primer A and primer E (5'-GTCTCCTTGCTCCGCCG-3') or primer F (5'-CGAAGTCTTCTATGAGCTGGCCCATG-3') and primer D. Aliquots of these two PCRs were then mixed and amplified with primers A and D. The resulting PCR product was digested with BamHI and MunI and ligated into pBABE-hygro-HA vector cut with BamHI and EcoRI.
###end p 27
###begin p 28
All plasmids were authenticated by DNA sequencing. pGL2-VEGF promoter plasmid was a kind gift from Dr. Deb Mukhopadhyay (Harvard Medical School, Boston, Massachusetts, United States). pSV-beta-Gal plasmid was purchased from Promega Corporation (Madison, Wisconsin, United States).
###end p 28
###begin title 29
Cell culture
###end title 29
###begin p 30
###xml 330 331 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 468 490 462 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>
###xml 419 422 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 450 453 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Renal carcinoma cell lines (786-O and A498) and Phoenix cells (a generous gift of Dr. Gary Nolan, Department of Molecular Pharmacology, Stanford University, Stanford, California, United States) were grown in Dulbecco's modified Eagle's medium containing 10% fetal clone I (Hyclone, Logan Utah, United States) in presence of 10% CO2 at 37degreesC. 786-O renal cell carcinoma subclones stably transfected with either pRc/CMV empty vector (PRC3) or pRc/CMV-HA-VHL (WT8) (Iliopoulos et al. 1995) were grown in the same media supplemented with 1 mg/ml G418. Retrovirally infected cells were selected and maintained in the presence of puromycin (1.5 mug/ml for pBABE-puro retroviruses or 1.0 mug/ml for pSUPER retroviruses) or hygromycin 0.5 mug/ml for pBABE-hygro retrovirus.
###end p 30
###begin title 31
Retroviruses.
###end title 31
###begin p 32
Retroviral plasmids were transfected into the Phoenix packaging cell line using FuGene (Roche Molecular Biochemicals) according to the manufacturer's instructions. Tissue culture supernatant was harvested 48 h later, passed though a 0.45-mum filter, and added to cells in the presence of 4 mug/ml polybrene.
###end p 32
###begin title 33
Immunoblot analysis
###end title 33
###begin p 34
###xml 520 526 <span type="species:ncbi:9986">rabbit</span>
###xml 635 640 <span type="species:ncbi:10090">mouse</span>
###xml 740 746 <span type="species:ncbi:9986">rabbit</span>
###xml 844 848 <span type="species:ncbi:9925">goat</span>
###xml 928 934 <span type="species:ncbi:9913">bovine</span>
###xml 983 994 <span type="species:ncbi:3704">horseradish</span>
###xml 1017 1021 <span type="species:ncbi:9925">goat</span>
###xml 1027 1033 <span type="species:ncbi:9986">rabbit</span>
###xml 1039 1043 <span type="species:ncbi:9925">goat</span>
###xml 1049 1054 <span type="species:ncbi:10090">mouse</span>
###xml 1063 1069 <span type="species:ncbi:9986">rabbit</span>
###xml 1075 1079 <span type="species:ncbi:9925">goat</span>
Cells were lysed in EBC lysis buffer (50 mM Tris [pH 8.0], 120 mM NaCl, 0.5% NP-40) supplemented with complete protease inhibitor cocktail (Roche Molecular Biochemicals). Approximately 300 mug of cell extract per lane, as determined by the Bradford method, was resolved by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, California, United States). After blocking in Tris-buffered saline (TBS) with 4% nonfat milk, the membranes were probed with anti-HA rabbit polyclonal antibody (Y-11; Santa Cruz Biotechnology, Santa Cruz, California, United States), anti-HIF2alpha mouse monoclonal antibody (NB100-132; Novus Biologicals, Littleton, Colorado, United States), anti-GLUT1 rabbit polyclonal antibody (GT11-A; Alpha Diagnostic, San Antonio, Texas, United States), or anti-actin goat polyclonal antibody (sc-1615; Santa Cruz Biotechnology) diluted in TBS with 4% bovine serum albumin. Bound antibody was detected with horseradish peroxidase-conjugated goat anti-rabbit IgG, goat anti-mouse IgG, or rabbit anti-goat IgG (Pierce, Rockford, Illinois, United States) and SuperSignal West Pico chemiluminescent substrate (Pierce) according to the manufacturer's instructions.
###end p 34
###begin title 35
In vitro proliferation assays
###end title 35
###begin p 36
Approximately 5,000 cells were plated per well in 6-well plates and grown under the cell culture conditions described above. At various timepoints thereafter, cells were released by trypsinization, resuspended in phosphate-buffered saline (PBS), and stained with trypan blue. Viable cells, as determined by trypan blue exclusion, were counted using a hemocytometer.
###end p 36
###begin title 37
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nude</italic>
###xml 5 10 <span type="species:ncbi:10090">mouse</span>
Nude mouse xenograft assays
###end title 37
###begin p 38
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nude</italic>
###xml 67 89 67 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Iliopoulos1">Iliopoulos et al. 1995</xref>
###xml 91 108 91 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio.0000083-Kondo1">Kondo et al. 2002</xref>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 5 10 <span type="species:ncbi:10090">mouse</span>
###xml 290 299 <span type="species:ncbi:10090">nude mice</span>
###xml 332 337 <span type="species:ncbi:10090">mouse</span>
Nude mouse xenograft assays were performed as described elsewhere (Iliopoulos et al. 1995; Kondo et al. 2002). In brief, cells were released by trypsinization and resuspended in PBS. Viable cells (107), as determined by trypan blue staining, were injected subcutaneously into the flanks of nude mice. Both flanks were used for each mouse. The animals were sacrificed 8-10 wk after injection. Autopsy was performed by animal care technicians who were unaware of the HIF status of the tumors. Tumors were weighed, cut in half, and fixed in either formalin or frozen in optimal cutting temperature compound.
###end p 38
###begin p 39
We thank members of the Kaelin Laboratory for useful discussions and Rene Bernards for generously providing the pSUPER-retro plasmid prior to publication. WGK is a Howard Hughes Medical Institute investigator. This work was sponsored by the National Cancer Institute and the Murray Foundation.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
###end article-title 41
###begin article-title 42
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
###end article-title 42
###begin article-title 43
Stable suppression of tumorigenicity by virus-mediated RNA interference
###end article-title 43
###begin article-title 44
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
###end article-title 44
###begin article-title 45
###xml 82 87 <span type="species:ncbi:9606">human</span>
Mitogenic effects of EGF/TGF alpha and immunolocalization of cognate receptors in human fetal kidneys
###end article-title 45
###begin article-title 46
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
###end article-title 46
###begin article-title 47
VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling
###end article-title 47
###begin article-title 48
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
Role of transforming growth factor-alpha in VHL-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis
###end article-title 48
###begin article-title 49
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha
###end article-title 49
###begin article-title 50
Protein tyrosine kinase inhibitors: New treatment modalities?
###end article-title 50
###begin article-title 51
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Mutations of the VHL tumour suppressor gene in renal carcinoma
###end article-title 51
###begin article-title 52
###xml 82 85 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product
###end article-title 52
###begin article-title 53
Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor
###end article-title 53
###begin article-title 54
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
###end article-title 54
###begin article-title 55
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor
###end article-title 55
###begin article-title 56
###xml 25 30 <span type="species:ncbi:9606">human</span>
Tumor suppression by the human von Hippel-Lindau gene product
###end article-title 56
###begin article-title 57
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
###end article-title 57
###begin article-title 58
###xml 91 92 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing
###end article-title 58
###begin article-title 59
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
###end article-title 59
###begin article-title 60
Molecular basis of the VHL hereditary cancer syndrome
###end article-title 60
###begin article-title 61
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor
###end article-title 61
###begin article-title 62
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
###end article-title 62
###begin article-title 63
The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma
###end article-title 63
###begin article-title 64
Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2
###end article-title 64
###begin article-title 65
###xml 15 30 <span type="species:ncbi:10090">transgenic mice</span>
Renal cysts in transgenic mice expressing transforming growth factor-alpha
###end article-title 65
###begin article-title 66
###xml 121 129 <span type="species:ncbi:9606">patients</span>
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients
###end article-title 66
###begin article-title 67
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
###end article-title 67
###begin article-title 68
HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron
###end article-title 68
###begin article-title 69
Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroylation
###end article-title 69
###begin article-title 70
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
###end article-title 70
###begin article-title 71
The von Hippel-Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia-inducible factor alpha subunits
###end article-title 71
###begin article-title 72
###xml 131 136 <span type="species:ncbi:9606">human</span>
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and non-neoplastic human kidney tissue
###end article-title 72
###begin article-title 73
Vascular endothelial growth factor expression is increased in renal cell carcinoma
###end article-title 73
###begin article-title 74
###xml 71 76 <span type="species:ncbi:9606">human</span>
Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type
###end article-title 74
###begin article-title 75
###xml 102 107 <span type="species:ncbi:9606">human</span>
Differential response to transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types
###end article-title 75
###begin article-title 76
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
Induction of angiogenesis in a mouse model using engineered transcription factors
###end article-title 76
###begin article-title 77
HIF-1alpha is required for solid tumor formation and embryonic vascularization
###end article-title 77
###begin article-title 78
Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth
###end article-title 78
###begin article-title 79
A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
###end article-title 79
###begin article-title 80
Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
###end article-title 80
###begin article-title 81
Familial adult renal neoplasia
###end article-title 81
###begin article-title 82
###xml 29 35 <span type="species:ncbi:9986">rabbit</span>
Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor
###end article-title 82
###begin article-title 83
###xml 69 72 <span type="species:ncbi:10116">rat</span>
Altered expression of transforming growth factor-alpha in hereditary rat renal cell carcinoma
###end article-title 83
###begin article-title 84
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
###end article-title 84
###begin article-title 85
HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation
###end article-title 85
###begin article-title 86
A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size
###end article-title 86
###begin title 87
Abbreviations
###end title 87
###begin p 88
basic helix-loop-helix
###end p 88
###begin p 89
epidermal growth factor
###end p 89
###begin p 90
epidermal growth factor receptor
###end p 90
###begin p 91
egg-laying-defective nine
###end p 91
###begin p 92
glucose transporter 1
###end p 92
###begin p 93
hypoxia-inducible factor
###end p 93
###begin p 94
phosphate-buffered saline
###end p 94
###begin p 95
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
VHL gene product
###end p 95
###begin p 96
short hairpin RNA
###end p 96
###begin p 97
short interfering RNA
###end p 97
###begin p 98
Tris-buffered saline
###end p 98
###begin p 99
transforming growth factor
###end p 99
###begin p 100
vascular endothelial growth factor
###end p 100
###begin p 101
von Hippel-Lindau
###end p 101
###begin title 102
Figures and Tables
###end title 102
###begin title 103
HIF2alpha Overrides Tumor Suppression by pVHL
###end title 103
###begin p 104
###xml 243 244 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
(A) 786-O subclones that were transfected to produce wild-type pVHL (WT8) or with an empty plasmid (PRC3) cells, as well as WT8 cells infected with an empty retrovirus (Empty) or retroviruses encoding the indicated HIF2alpha variants [ (P-->A)2 = P405A;P531A and * = bHLH mutation] were grown in the presence of 21% or 1% oxygen and immunoblotted (IB) with the indicated antibodies.
###end p 104
###begin p 105
(B) In vitro proliferation of WT8 cells infected with the indicated retroviruses.
###end p 105
###begin p 106
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 126 135 <span type="species:ncbi:10090">nude mice</span>
(C) Tumor weights approximately 9 wk after subcutaneous implantation of WT8 cells infected with the indicated retroviruses in nude mice. Number of tumors analyzed is shown in parentheses. Error bars = one standard error.
###end p 106
###begin title 107
Downregulation of HIF2alpha Is Sufficient to Suppress Tumor Growth by pVHL-Defective Renal Carcinoma Cells
###end title 107
###begin p 108
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
(A) Parental 786-O cells (VHL[-/-]) and 786-O cells infected with an empty retrovirus (Empty) or retroviruses encoding HIF2alpha shRNAs (sequence #2 or #3) were grown in the presence of 21% or 1% oxygen and immunoblotted (IB) with the indicated antibodies.
###end p 108
###begin p 109
(B) In vitro proliferation of 786-O cells infected with the indicated retroviruses.
###end p 109
###begin p 110
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 128 137 <span type="species:ncbi:10090">nude mice</span>
(C) Tumor weights approximately 9 wk after subcutaneous implantation of 786-O cells infected with the indicated retroviruses in nude mice. Number of tumors analyzed is shown in parentheses. Error bars = one standard error.
###end p 110
###begin p 111
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
(D) Representative photograph of nude mouse 9 wk after subcutaneous injection of 786-O cells in left (upper) flank and 786-O cells infected with HIF2alpha shRNA (#3) retrovirus on right (lower) flank.
###end p 111
###begin title 112
Effect of HIF2alpha shRNA Is Specifically Due to Downregulation of HIF2alpha
###end title 112
###begin p 113
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
(A) Parental 786-O cells (VHL[-/-]) and 786-O cells stably producing HIF2alpha shRNA #3 that were coinfected with an empty retrovirus (Empty) or a retrovirus encoding a HIF2alpha mRNA with three silent mutations in the #3 recognition site (MT*) were grown in the presence of 21% or 1% oxygen and immunoblotted (IB) with the indicated antibodies.
###end p 113
###begin p 114
(B) In vitro proliferation of 786-O HIF2alpha shRNA #3 cells infected with the indicated retroviruses.
###end p 114
###begin p 115
###xml 144 148 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 144 153 <span type="species:ncbi:10090">nude mice</span>
(C) Tumor weights approximately 9 wk after subcutaneous implantation of 786-O HIF2alpha shRNA cells infected with the indicated retroviruses in nude mice. Number of tumors analyzed is shown in parentheses. Error bars = one standard error.
###end p 115
###begin p 116
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
(D) Representative photograph of nude mouse 9 wk after subcutaneous injection of 786-O HIF2alpha shRNA #3 cells in left (upper) flank and 786-O HIF2alpha shRNA #3 cells infected with retrovirus encoding HIF2alpha MT* mRNA on right (lower) flank.
###end p 116
###begin title 117
Tumor Suppression by HIF2alpha shRNA Is Not Restricted to a Single Cell Line
###end title 117
###begin p 118
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nude</italic>
###xml 127 136 <span type="species:ncbi:10090">nude mice</span>
(A) Tumor weights approximately 8 wk after subcutaneous implantation of A498 cells infected with the indicated retroviruses in nude mice. Number of tumors analyzed is shown in parentheses. Error bars = one standard error.
###end p 118
###begin p 119
(B) Representative histological sections after staining with hematoxylin and eosin of tumors formed by A498 cells infected with the indicated retroviruses.
###end p 119
###begin p 120
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflicts of interest.</bold>
Conflicts of interest. The authors have declared that no conflicts of interest exist.
###end p 120
###begin p 121
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. KK and WGK conceived and designed the experiments. KK, WYK, and ML performed the experiments. KK, ML, and WGK analyzed the data. KK contributed reagents/materials/analysis tools. WYK and WGK wrote the paper.
###end p 121
###begin p 122
Academic Editor: Christopher Kemp, Fred Hutchinson Cancer Research Center
###end p 122

